What it's for (Indications)
- Hexahydroadiphenine + Propyphenazone is indicated for the symptomatic relief of pain associated with spasm of smooth musculature.
- This includes, but is not limited to, conditions affecting the gastrointestinal tract such as irritable bowel syndrome, biliary colic, gastroenteritis-associated spasms, and diverticular disease.
- It is also used for genitourinary tract spasms, including renal and ureteric colic, bladder spasms, and dysmenorrhea.
- The combination provides both antispasmodic action to relax smooth muscles and analgesic properties to alleviate pain, making it suitable for acute and chronic conditions characterized by visceral pain and hypermotility.
- Its therapeutic profile targets both the cause (spasm) and the symptom (pain) simultaneously, offering comprehensive relief for various spastic pain syndromes.
- This therapeutic combination is typically reserved for conditions where both components' actions are medically justified and beneficial.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of Hexahydroadiphenine + Propyphenazone must be individualized based on the patient's age, severity of symptoms, and response to treatment. For adults, a typical oral dosage often ranges from 1 to 2 tablets, taken up to three times daily, usually with or immediately after meals to mitigate potential gastrointestinal discomfort. It is crucial not to exceed the maximum daily dose specified in the product's official prescribing information, which limits the total intake of both active components to prevent accumulation and adverse effects. It is imperative to administer the lowest effective dose for the shortest possible duration to minimize potential adverse effects, particularly the hematological risks associated with propyphenazone. Specific dosage adjustments may be necessary for patients with impaired renal or hepatic function, and for elderly individuals who may be more susceptible to anticholinergic side effects and other adverse reactions. Patients should always consult a healthcare professional for precise dosage instructions tailored to their specific medical condition and should never self-adjust or exceed recommended doses. |
Safety & Warnings
Common Side Effects
- Adverse effects associated with Hexahydroadiphenine + Propyphenazone can be attributed to either component.
- Common anticholinergic side effects from hexahydroadiphenine include dry mouth, blurred vision, cycloplegia, increased intraocular pressure, urinary retention, constipation, and tachycardia.
- Central nervous system effects such as dizziness, drowsiness, headache, and rarely, confusion or hallucinations, particularly in elderly or susceptible patients, may occur.
- Propyphenazone, a pyrazolone derivative, can lead to gastrointestinal disturbances like nausea, vomiting, dyspepsia, and abdominal pain.
- Hypersensitivity reactions are a significant concern and can manifest as skin rashes, urticaria, pruritus, angioedema, and in severe cases, bronchospasm or anaphylactic shock.
- More serious but less common adverse effects include hematological abnormalities such as leukopenia, thrombocytopenia, and critically, agranulocytosis, which may be life-threatening.
- Other potential effects include renal impairment, hepatic dysfunction, and hypotension.
- Patients should be advised to seek immediate medical attention if they experience severe allergic reactions, signs of bleeding, unusual bruising, or any symptoms suggestive of infection.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: RISK OF AGRANULOCYTOSIS AND SEVERE HYPERSENSITIVITY REACTIONS** Although Hexahydroadiphenine + Propyphenazone may not carry a formal FDA Black Box Warning in all regions where it is approved, it contains Propyphenazone, a pyrazolone derivative, which is associated with a significant and potentially life-threatening risk of agranulocytosis. Agranulocytosis is a severe form of leukopenia (a drastic decrease in white blood cells, particularly granulocytes) that renders patients highly susceptible to overwhelming, potentially fatal infections. This adverse reaction can occur suddenly, is generally not dose-dependent, and may manifest even after a single dose or following prolonged treatment. Patients must be educated to immediately report any signs or symptoms suggestive of infection (e.g., fever, chills, sore throat, mouth ulcers, flu-like symptoms, unexplained weakness) and to discontinue the medication at once. Regular monitoring of complete blood counts with differential, especially the granulocyte count, is strongly recommended during prolonged therapy or if any signs of hematological abnormality are observed. In addition to agranulocytosis, severe hypersensitivity reactions, including anaphylactic shock, angioedema, and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome or toxic epidermal necrolysis, have been reported with pyrazolone derivatives. These reactions can be rapid in onset, unpredictable, and life-threatening. Emergency medical attention is required for any signs of severe allergic reaction, such as difficulty breathing, swelling of the face or throat, widespread urticaria or rash, or sudden drop in blood pressure. The benefits of using this medication must be carefully weighed against these significant and potentially fatal risks, and its use should be restricted to situations where safer alternatives are inadequate or contraindicated.
- This combination product should be used with extreme caution in patients with a history of hypersensitivity to pyrazolones, NSAIDs, or anticholinergic agents, as severe allergic reactions including anaphylaxis can occur.
- Patients with pre-existing conditions such as glaucoma (especially narrow-angle), prostatic hypertrophy, or urinary obstruction are at increased risk of exacerbation due to the anticholinergic effects of hexahydroadiphenine, potentially leading to acute urinary retention or increased intraocular pressure.
- Cardiac patients, particularly those with tachyarrhythmias, congestive heart failure, or uncontrolled hypertension, should be closely monitored due to the potential for anticholinergic-induced tachycardia.
- Propyphenazone carries a risk of hematological dyscrasias, including agranulocytosis; therefore, regular blood count monitoring is advisable during prolonged treatment or in patients exhibiting any signs of infection (e.
- g.
- , fever, sore throat, flu-like symptoms).
- Caution is also warranted in patients with impaired renal or hepatic function, as accumulation of the drugs or their metabolites may occur, increasing toxicity risk.
- Concurrent use with other anticholinergic drugs, CNS depressants, or alcohol should be avoided due to additive effects and increased risk of adverse reactions.
- Patients should be warned about potential impairment of their ability to drive or operate machinery due to dizziness, drowsiness, or blurred vision.
- Discontinuation of the drug is recommended at the first sign of any adverse hematological changes or severe hypersensitivity reactions.
How it Works (Mechanism of Action)
Hexahydroadiphenine + Propyphenazone provides a dual mechanism of action to comprehensively address spasmodic pain. Hexahydroadiphenine functions as an anticholinergic agent, specifically a muscarinic receptor antagonist. It competitively blocks the action of acetylcholine at peripheral muscarinic receptors located on smooth muscle cells, particularly within the gastrointestinal, biliary, and genitourinary tracts. This blockade leads to relaxation of the smooth musculature, thereby reducing spasm and alleviating the associated pain and discomfort. By inhibiting parasympathetic nerve impulses, it decreases motility and tone in these organs, effectively relieving spastic conditions. Propyphenazone is a pyrazolone derivative with analgesic and antipyretic properties. While its precise mechanism is not fully elucidated, it is believed to primarily act by inhibiting prostaglandin synthesis, similar to non-steroidal anti-inflammatory drugs (NSAIDs), though it may exhibit preferential central action or affect different prostaglandin pathways (e.g., COX-3). This inhibition reduces the production of inflammatory mediators that sensitize pain receptors, thus exerting its pain-relieving effect. The combined action of smooth muscle relaxation and pain modulation offers comprehensive relief for conditions characterized by visceral spasm and associated pain.
Commercial Brands (Alternatives)
No other brands found for this formula.